Literature DB >> 7515854

Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.

N E Rhaleb1, X P Yang, A G Scicli, O A Carretero.   

Abstract

We examined the effect of non-antihypertensive doses of the angiotensin-converting enzyme inhibitor ramipril, kinins, and/or nitric oxide on left ventricular hypertrophy in rats with aortic coarctation. We investigated the effect of either HOE 140, a specific B2 receptor antagonist, or NG-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, on the antihypertrophic effect of ramipril at non-antihypertensive doses (10 micrograms/kg per day) failed to alter left ventricular hypertrophy significantly, although a small decrease was obtained. Given at a dose of 1 mg/kg per day for 6 weeks, ramipril prevented increased blood pressure and left ventricular hypertrophy after aortic coarctation. Neither of these effects was blocked by simultaneous administration of HOE 140 (500 micrograms/kg per day). In rats with aortic coarctation treated with L-NAME, blood pressure increased further but left ventricular weight did not. Ramipril (1 mg/kg per day) significantly reduced left ventricular hypertrophy, although blood pressure was still higher than in rats given water alone. The slope of the correlation between left ventricular weight and blood pressure in rats that received L-NAME was significantly lower than in rats that did not (0.52 versus 1.29; P = .008). This suggests that for each 1 mm Hg that the blood pressure increased, the increase in left ventricular weight was less in the L-NAME groups. Thus, only antihypertensive doses of ramipril possessed antihypertrophic activity. Kinins did not participate in the chronic antihypertensive and antihypertrophic effects of ramipril. In hypertension induced or aggravated by chronic nitric oxide synthase, L-NAME partially impaired development of left ventricular hypertrophy for reasons that are unclear.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515854     DOI: 10.1161/01.hyp.23.6.865

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

Authors:  Y H Liu; X P Yang; V G Sharov; O Nass; H N Sabbah; E Peterson; O A Carretero
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

Review 2.  Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life.

Authors:  M E Cooper; D Vranes; J R Rumble
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

Review 3.  The renin-angiotensin system and the heart: beyond 2000.

Authors:  T Morgan; H R Brunner
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

4.  Role of bradykinin in the antihypertrophic effects of enalapril in the newborn pig heart.

Authors:  C J Beinlich; C J Rissinger; K J Vitkauskas; H E Morgan
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

5.  The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension.

Authors:  B B Matsubara; L S Matsubara; M Franco; J C Padovani; J S Janicki
Journal:  Int J Exp Pathol       Date:  1999-04       Impact factor: 1.925

Review 6.  The kallikrein-kinin system as a regulator of cardiovascular and renal function.

Authors:  Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

7.  Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension.

Authors:  Hongmei Peng; Oscar A Carretero; David R Brigstock; Nancy Oja-Tebbe; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2003-10-27       Impact factor: 10.190

Review 8.  Role of Kinins in Hypertension and Heart Failure.

Authors:  Suhail Hamid; Imane A Rhaleb; Kamal M Kassem; Nour-Eddine Rhaleb
Journal:  Pharmaceuticals (Basel)       Date:  2020-10-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.